Generic Versions Of Rytary Should Meet 3 Extra Standards, Impax Says
Executive Summary
US FDA should refrain from relying on standard PK measurements for determining bioequivalence for the extended-release Parkinson's product.
You may also be interested in...
Citizen Petitions Targeting ANDAs Recede, But Concerns Over Resources Remain
FDA worries about diverting resources to respond to 505(q) petitions, despite receiving lowest number in fiscal year 2015 since it began tracking requests.
Xpovio Avoided Complete Response Letter Through Late-Cycle Submission Of BOSTON Data
After US FDA's Oncologic Drugs Advisory Committee voted to delay approval of Karyopharm's multiple myeloma drug Xpovio, the company submitted some data from the Phase III BOSTON trial, which prompted the FDA to award an accelerated approval for a narrower indication.
Xpovio Clinical Development Timeline
Chronicle of the development and review of Karyopharm's Xpovio (selinexor) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies.